|1.||Bouillet, Laurence: 6 articles (09/2015 - 11/2009)|
|2.||Maurer, Marcus: 6 articles (09/2015 - 04/2010)|
|3.||Hoffmann, Thomas K: 6 articles (07/2015 - 08/2010)|
|4.||Calixto, J B: 5 articles (08/2015 - 07/2007)|
|5.||Bas, Murat: 5 articles (07/2015 - 05/2010)|
|6.||Greve, Jens: 5 articles (07/2015 - 08/2010)|
|7.||Pesquero, João B: 5 articles (09/2011 - 05/2002)|
|8.||Zanichelli, Andrea: 4 articles (09/2015 - 08/2010)|
|9.||Kojda, G: 4 articles (03/2015 - 12/2006)|
|10.||Lumry, William R: 4 articles (01/2015 - 12/2011)|
08/01/2011 - "A short-cut review was carried out to establish whether icatibant is effective in the treatment of hereditary angioedema. "
06/01/2007 - "Icatibant was effective in treating acute attacks of hereditary angioedema. "
11/01/2012 - "Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial."
01/01/2010 - "Across both FAST-1 and -2, the efficacy of subcutaneous icatibant 30 mg in the treatment of laryngeal episodes of hereditary angioedema was generally consistent with that seen for abdominal and cutaneous episodes, with a median time to first symptom improvement of 0.6-1.0 hours. "
01/01/2004 - "Positive results from an icatibant formulation comparative study, in patients with acute attacks of hereditary angioedema, were announced in August 2004; IV and SC formulations showed no difference in efficacy and safety. "
10/10/2011 - "Randomised, controlled trials are warranted to document the efficacy of icatibant in ACE-i angioedema."
09/01/2015 - "Commentary regarding: A randomized trial of icatibant in ACE-inhibitor-induced angioedema."
01/29/2015 - "A randomized trial of icatibant in ACE-inhibitor-induced angioedema."
01/01/2015 - "Here, the efficacy and safety of icatibant for multiple HAE attacks was evaluated across the controlled and open-label extension phases of the For Angioedema Subcutaneous Treatment (FAST)-3 study (NCT00912093). "
08/01/2014 - "The open-label extension (OLE) phase of the For Angioedema Subcutaneous Treatment (FAST)-1 trial (NCT00097695) evaluated the efficacy and safety of repeated icatibant exposure in adults with multiple HAE attacks. "
01/01/2009 - "For the 41 patients with OA, an analgesic effect of icatibant could clearly be shown, especially for pain during activity in the high dose icatibant group. "
11/01/2014 - "In conclusion, the results suggest that bradykinin type 2 receptor antagonists such as HOE 140 could be useful in the treatment of acute inflammatory pain. "
11/01/2014 - "Locally mediated analgesic effect of bradykinin type 2 receptor antagonist HOE 140 during acute inflammatory pain in rats."
08/01/1994 - "The pain elicited by the extract is solely mediated by kinins and can be prevented by icatibant. "
09/01/1993 - "When Hoe 140 was injected subcutaneously 30 min before formalin injection (9.9 and 99 nmol kg-1), it significantly attenuated both phases of formalin-induced pain. "
09/01/1998 - "A known B2-antagonist, Hoe 140, also significantly suppressed this edema. "
11/01/2011 - "After a subcutaneous injection of icatibant, the situation improved very rapidly, with a regression of the edema. "
01/29/2015 - "Significantly more patients in the icatibant group than in the standard-therapy group had complete resolution of edema within 4 hours after treatment (5 of 13 vs. 0 of 14, P=0.02). "
01/29/2015 - "Among patients with ACE-inhibitor-induced angioedema, the time to complete resolution of edema was significantly shorter with icatibant than with combination therapy with a glucocorticoid and an antihistamine. "
07/01/2012 - "SpV-induced edema was reduced significantly by previous administration of aprotinin or icatibant (HOE-140). "
03/01/2002 - "Immunohistochemical staining of tumor tissues with an anti-BK B2 receptor antibody, or autoradiography with the B2 receptor antagonist [125I]HOE 140 (D-Arg-[Hyp Thi D-Tic Oic8]-BK) and the B2 receptor agonist [3H]BK indicated the presence of B2 receptors in all human tumor cells and murine S-180 and C-38 cells. "
01/01/1998 - "administration of HOE 140 at 13 microg/kg/12 h initiated immediately after tumor inoculation significantly suppressed formation of S-180 tumor ascites; the life span of ascitic S-180 tumor-bearing mice was prolonged at the same dose of HOE 140. "
01/01/1998 - "More importantly, bradykinin antagonists such as HOE 140 may be beneficial for the inhibition of tumor growth."
12/01/2001 - "Daily administration of bradykinin B2-receptor antagonists, Hoe140 (0.1 and 1 mg/kg per day, local injection) or FR173657 (30 mg/kg per day, p.o.), significantly suppressed the increment in angiogenesis and tumor weight, but a B1-receptor antagonist, desArg10-Hoe140 (1 mg/kgperday), did not. "
01/01/1998 - "In the S-180 solid tumor model, administration of HOE 140 (0.65 or 1.3 microg/kg/8 h, s.c.), PTIO (167 mg/kg/2 h, four times/8 h, i.p.), or indomethacin (5 or 10 mg/kg/day, three times, i.p.) significantly suppressed the EPR effect in the tumor, and the combined administration of these agents achieved a stronger inhibition of the EPR effect than did each compound alone. "
|2.||Bradykinin B2 Receptor
|3.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|4.||2,5-dichloro-4-bromophenol (B 2)
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|8.||Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)
|9.||(4- amino- 5- (4- (4- (2,4- dichloro- 3- (2,4- dimethyl- 8- quinolyloxymethyl)phenylsulfonamido)tetrahydro- 2H- 4- pyranoylcarbonyl)piperazino)- 5- oxopentyl)(trimethyl)ammonium
|2.||Self Administration (Administration, Self)
|4.||Indwelling Catheters (Arterial Line)